Subtyping EGFR-mutated NSCLC Patients with Adjuvant TKIs or Chemotherapy Using Deep Radiomic Signatures

被引：0
|
作者：
Qi, Y. -F. [1 ,2 ]
Li, J. [3 ]
Qiu, Z. -B. [1 ,2 ]
Wu, Y. -L. [1 ,2 ]
Zhang, X. [3 ]
Zhong, W. -Z. [1 ,2 ]
机构：
[1] Southern Med Univ, Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
[2] South China Univ Technol, Guangzhou, Peoples R China
[3] Tsinghua Univ, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Non-small cell lung cancer; Epidermal growth factor receptor; Radiomics;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-01
引用
收藏
页码：S565 / S566
页数：2
相关论文
共 50 条
  • [21] Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases
    Zhang, Jinyao
    Wang, Yan
    Liu, Ziling
    Wang, Lin
    Yao, Yu
    Liu, Yutao
    Hao, Xue Zhi
    Wang, Jianyang
    Xing, Puyuan
    Li, Junling
    THORACIC CANCER, 2021, 12 (24) : 3407 - 3415
  • [22] Clinical analysis of the presence of comutations in patients with EGFR-mutated NSCLC
    Rubio, Jaime
    Santolaya, Carlota
    Fernandez, Marina
    Villalba, Paula Lucia
    Avedillo, Mercedes
    Garcia-Foncillas, Jesus
    Domine, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer A meta-analysis
    Huang, Lei
    Huang, Hao
    Zhou, Xiao-Ping
    Liu, Jin-Feng
    Li, Chun-Rong
    Fang, Min
    Wu, Jun-Rong
    MEDICINE, 2019, 98 (43)
  • [24] Effect of longitudinal ctDNA monitoring with resistance genomic signatures on prognostication in patients with EGFR-mutated advanced NSCLC
    Prabhash, Kumar
    Bharde, Atul
    Behel, Vichitra
    Ratnaparkhi, Mrunal
    Noronha, Vanita
    Patil, Vijay Maruti
    Choughule, Anuradha
    Chandrani, Pratik
    Dutt, Amit
    Jadhav, Bhagwat
    Prajapati, Sangeeta
    Haldar, Sumit
    Mobeen, Fauzul
    Menon, Nandini Sharrel
    Hariramani, Kanchan
    Basavalingegowda, Madhura
    Chaturvedi, Pankaj
    Khandare, Jayant
    Shafi, Gowhar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
    Wen, Miaomiao
    Xia, Jinghua
    Sun, Ying
    Wang, Xuejiao
    Fu, Xianghui
    Zhang, Yanning
    Zhang, Zhipei
    Zhou, Yongan
    Li, Xiaofei
    BIOLOGICS-TARGETS & THERAPY, 2018, 12 : 183 - 190
  • [26] Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives
    Rebuzzi, Sara Elena
    Alfieri, Roberta
    La Monica, Silvia
    Minari, Roberta
    Petronini, Pier Giorgio
    Tiseo, Marcello
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 146
  • [27] Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients
    Yan, Han
    Li, Qin
    Wang, Wei
    Zhen, Hongchao
    Cao, Bangwei
    SCIENTIFIC REPORTS, 2015, 5
  • [28] Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients
    Han Yan
    Qin Li
    Wei Wang
    Hongchao Zhen
    Bangwei Cao
    Scientific Reports, 5
  • [29] Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells
    Furugaki, Koh
    Iwai, Toshiki
    Moriya, Yoichiro
    Harada, Naoki
    Fujimoto-Ouchi, Kaori
    LUNG CANCER, 2014, 83 (01) : 44 - 50
  • [30] EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis (vol 24, 1390, 2024)
    Liu, Ao
    Wang, Xiaoming
    Wang, Lian
    Zhuang, Han
    Xiong, Liubo
    Gan, Xiao
    Wang, Qian
    Tao, Guanyu
    BMC CANCER, 2025, 25 (01)
12345